New Mass Spectrometry Method Finds Rare Bacterial Peptides That Could Guide Vaccine Design

A new data-independent acquisition (DIA) mass spectrometry approach dramatically improved the detection of rare bacterial peptides displayed on immune cells. Using Listeria monocytogenes as a model pathogen, researchers showed that DIA workflows found additional human and bacterial immunopeptides missed by the standard data-dependent (DDA) method. Their most powerful approach used DIA-NN software to generate and search predicted peptide libraries covering approximately 150 million immunopeptide precursors, outperforming all other methods at identifying MHC class I peptides — the molecular targets that guide vaccine and immunotherapy design.

Researchers compared two mass spectrometry approaches — data-independent acquisition (diaPASEF) versus conventional data-dependent acquisition (ddaPASEF) — for profiling immunopeptides from cells infected with Listeria monocytogenes. They tested DIA spectrum-centric workflows and also used DIA-NN software to generate proteome-wide predicted HLA class I peptide spectral libraries, scoring approximately 150 million peptide precursors to identify both abundant and rare immunopeptides.

Finding the right peptide targets is the critical first step in designing vaccines and immunotherapies. Many important bacterial peptides are present in very low amounts on cell surfaces, making them invisible to standard detection methods. This improved approach can identify these rare peptide targets, potentially accelerating the development of vaccines against intracellular pathogens and expanding the pool of targets available for cancer immunotherapy.

Immunopeptidomics — the comprehensive study of peptides displayed on cell surfaces for immune recognition — is foundational to both vaccine development and cancer immunotherapy. By making it possible to detect rare peptide targets that standard methods miss, this technology could expand the repertoire of targets available for next-generation vaccines against intracellular pathogens and personalized cancer treatments.

This is a methods development study using a single model pathogen (Listeria monocytogenes). The approach needs validation across other pathogens and in clinical settings. The computational demands of searching 150 million precursors may limit accessibility. Peptide identification does not guarantee immunogenicity — the peptides still need biological validation to confirm they trigger immune responses.